Search results for "Microbispora sp."
showing 7 items of 7 documents
Metabolic pathways in Microbispora sp. ATCC-PTA 5024, producer of NAI-107 lantibiotic
2014
Regulatory and metabolic proteins differentially expressed during NAI-107 production in Microbispora sp. ATCC-PTA 5024
2014
Metabolic pathways and regulatory networks associated to NAI-107 lantibiotic production in Microbispora sp. ATCC-PTA-5024
2015
The filamentous actinobacterium Microbispora sp. ATCC-PTA-5024 produces the lantibiotic NAI-107, which is effective against multidrugresistant Gram-positive pathogens. In actinomycetes, the biosynthesis of antibiotics is elicited as a physiological response that is controlled by a complex regulatory network involving general and pathwayspecific regulators. The ‘omics technologies can be useful to explore molecular physiology in bacterial cells and elucidate molecular and metabolic events associated to antibiotic production in order to develop robust and economically-feasible production processes. To this aim, differential proteomic analyses, based two-dimensional difference in gel electroph…
Proteomics to elucidate the molecular physiology of Microbispora sp. ATCC-PTA-5024, the producer of NAI-107, a very promising lantibiotic
2015
The filamentous actinobacterium Microbispora sp. ATCC-PTA-5024 produces the lantibiotic NAI-107 (Maffioli et al., 2014), which is effective against multidrug-resistant Gram-positive pathogens (Jabés et al., 2011). In actinomycetes, the biosynthesis of antibiotics is generally elicited as a physiological response controlled by a complex regulatory network involving global regulators, playing pleiotropic roles, and pathway-specific regulators, which activate the biosynthesis of biologically active molecules (Bibb, 2005)
Draft Genome Sequence of the Microbispora sp. Strain ATCC-PTA-5024, Producing the Lantibiotic NAI-107.
2014
ABSTRACT We report the draft genome sequence of Microbispora sp. strain ATCC-PTA-5024, a soil isolate that produces NAI-107, a new lantibiotic with the potential to treat life-threatening infections caused by multidrug-resistant Gram-positive pathogens. The draft genome of strain Microbispora sp. ATCC-PTA-5024 consists of 8,543,819 bp, with a 71.2% G+C content and 7,860 protein-coding genes.